TFFP - TFF Pharmaceuticals completes dosing in early-stage Voriconazole Inhalation Powder study

TFF Pharmaceuticals (NASDAQ:TFFP) announces the completion of dosing in the Phase 1b trial of Voriconazole Inhalation Powder ((TFF VORI)) for the treatment and prevention of Invasive Pulmonary Aspergillosis (IPA). Patients with asthma and a portion of patients with cystic fibrosis and chronic obstructive pulmonary disease (COPD) are susceptible to IPA infections. Initial data from the study suggests that TFF VORI is well tolerated in asthma patients, supporting the company’s progress to Phase 2 study in IPA patients. This suggests TFF VORI also may have the potential to treat Allergic Bronchopulmonary Aspergillosis (ABPA) indication which impacts up to 2.5% of asthma patients. Shares up marginally premarket.

For further details see:

TFF Pharmaceuticals completes dosing in early-stage Voriconazole Inhalation Powder study